{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T22:41:34Z","timestamp":1794004894123,"version":"4.8.0"},"reference-count":120,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019718","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019718","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Nucleus Global"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Following myocardial infarction (MI), reperfusion strategies ensure that blood flow is promptly restored to salvage the ischaemic myocardium. However, the sudden restoration of blood flow can inflict further damage to the ischaemic tissue, known as myocardial ischaemia\/reperfusion injury (MIRI). Therapeutic strategies aimed at reducing MIRI and promoting cardiac repair remain an important clinical need. Protein-based therapies might exert benefits that limit damage and promote cardiac repair post-MI. To explore this further, we performed a systematic review of data from preclinical studies and clinical trial registries evaluating the cardioprotective effects of proteins post-MI. Medline and EMBASE were searched for preclinical studies that examined the potential cardioprotective effects of protein-based therapies to limit damage and\/or mediate cardiac repair when administered after MI and\/or reperfusion. Studies registered with ClinicalTrials.gov and EudraCT were also reviewed. In total, 84 studies were included in the final analysis, which included 46 different proteins. Overall, our findings support the concept that transiently applying recombinant or modified proteins after acute MI has the potential to promote lasting improvements in heart function via multiple pleiotropic mechanisms. Many of these proteins converge on a limited set of well-established signalling pathways involved in cardiac repair and remodelling after MI, with a few proteins demonstrating consistent and robust effects across multiple outcomes and models (small and large animals; reperfused and non-reperfused models). Despite this, the high potential cardioprotective benefit reported in preclinical studies has not translated into approved therapies for use in patients. Although the previous failure of protein therapies in clinical development does not invalidate the potential relevance of their downstream pathways, our research underlines the challenges in translating preclinical findings of protein-based therapies into the clinical setting. Future preclinical and clinical research should examine the optimal treatment effect and fully characterize the therapeutic potential of proteins involved in post-MI remodelling.<\/jats:p>","DOI":"10.1093\/cvr\/cvag100","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T11:36:35Z","timestamp":1778153795000},"page":"1143-1158","source":"Crossref","is-referenced-by-count":2,"title":["Proteins targeting ischaemic-reperfusion injury and repair after myocardial infarction: a systematic literature review"],"prefix":"10.1093","volume":"122","author":[{"given":"Asparuh","family":"Gardev","sequence":"first","affiliation":[{"name":"Boehringer Ingelheim International GmbH , Binger Stra\u00dfe 173, 55216 Ingelheim am Rhein ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek J","family":"Hausenloy","sequence":"additional","affiliation":[{"name":"Cardiovascular & Metabolic Disorders Program, Duke-National University of Singapore Medical School , Singapore ,","place":["Singapore"]},{"name":"National Heart Research Institute Singapore, National Heart Centre , Singapore ,","place":["Singapore"]},{"name":"Yong Loo Lin School of Medicine, National University Singapore , Singapore ,","place":["Singapore"]},{"name":"The Hatter Cardiovascular Institute, University College London , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9045-4740","authenticated-orcid":false,"given":"Anton","family":"Pekcec","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Pharma GmbH & Co. KG, Cardio-Renal-Metabolic Disease Discovery Research, Birkendorfer Str. 65, 88397 Biberach ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,7]]},"reference":[{"key":"2026062610073748900_cvag100-B1","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1016\/j.jacc.2019.10.009","article-title":"The global burden of cardiovascular diseases and risk factors: 2020 and beyond","volume":"74","author":"Mensah","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026062610073748900_cvag100-B2","volume-title":"Global Burden of Disease 2021: Findings from the GBD 2021 Study","author":"Institute for Health Metrics and Evaluation","year":"2024"},{"key":"2026062610073748900_cvag100-B3","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1093\/eurjpc\/zwab213","article-title":"Burden of ischemic heart disease and its attributable risk factors in 204 countries and territories, 1990\u20132019","volume":"29","author":"Safiri","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"2026062610073748900_cvag100-B4","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.pcad.2024.01.017","article-title":"The spectrum of post-myocardial infarction care: from acute ischemia to heart failure","volume":"82","author":"Akhtar","year":"2024","journal-title":"Prog Cardiovasc Dis"},{"key":"2026062610073748900_cvag100-B5","doi-asserted-by":"crossref","first-page":"430","DOI":"10.3892\/etm.2022.11357","article-title":"Myocardial ischemia\/reperfusion injury: mechanisms of injury and implications for management (review)","volume":"23","author":"He","year":"2022","journal-title":"Exp Ther Med"},{"key":"2026062610073748900_cvag100-B6","doi-asserted-by":"crossref","first-page":"8405370","DOI":"10.1155\/2020\/8405370","article-title":"Ischemia\/reperfusion injury: pathophysiology, current clinical management, and potential preventive approaches","volume":"2020","author":"S\u00e1nchez-Hern\u00e1ndez","year":"2020","journal-title":"Mediators Inflamm"},{"key":"2026062610073748900_cvag100-B7","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1016\/j.jacc.2024.02.056","article-title":"Reperfusion injury in patients with acute myocardial infarction: JACC scientific statement","volume":"83","author":"Welt","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026062610073748900_cvag100-B8","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur Heart J"},{"key":"2026062610073748900_cvag100-B9","article-title":"The cardiac wound healing response to myocardial infarction","volume":"15","author":"Chalise","year":"2023","journal-title":"WIREs Mech Dis"},{"key":"2026062610073748900_cvag100-B10","doi-asserted-by":"crossref","first-page":"1084460","DOI":"10.3389\/fimmu.2022.1084460","article-title":"The role of major immune cells in myocardial infarction","volume":"13","author":"Feng","year":"2023","journal-title":"Front Immunol"},{"key":"2026062610073748900_cvag100-B11","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s12964-023-01105-4","article-title":"Crosstalk between macrophages and cardiac cells after myocardial infarction","volume":"21","author":"Jian","year":"2023","journal-title":"Cell Commun Signal"},{"key":"2026062610073748900_cvag100-B12","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.molmed.2020.10.002","article-title":"Intercellular communication in the heart: therapeutic opportunities for cardiac ischemia","volume":"27","author":"Martins-Marques","year":"2021","journal-title":"Trends Mol Med"},{"key":"2026062610073748900_cvag100-B13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.molimm.2024.02.007","article-title":"Recent advances in potential targets for myocardial ischemia reperfusion injury: role of macrophages","volume":"169","author":"Zhuang","year":"2024","journal-title":"Mol Immunol"},{"key":"2026062610073748900_cvag100-B14","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/s41418-023-01252-8","article-title":"TREM2 macrophage promotes cardiac repair in myocardial infarction by reprogramming metabolism via SLC25A53","volume":"31","author":"Gong","year":"2024","journal-title":"Cell Death Differ"},{"key":"2026062610073748900_cvag100-B15","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/nm.3778","article-title":"Myeloid-derived growth factor (C19orf10) mediates cardiac repair following myocardial infarction","volume":"21","author":"Korf-Klingebiel","year":"2015","journal-title":"Nat Med"},{"key":"2026062610073748900_cvag100-B16","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1161\/CIRCULATIONAHA.120.053365","article-title":"Myeloid-derived growth factor protects against pressure overload-induced heart failure by preserving sarco\/endoplasmic reticulum ca(2+)-ATPase expression in cardiomyocytes","volume":"144","author":"Korf-Klingebiel","year":"2021","journal-title":"Circulation"},{"key":"2026062610073748900_cvag100-B17","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s44161-023-00411-x","article-title":"Cysteine-rich with EGF-like domains 2 (CRELD2) is an endoplasmic reticulum stress-inducible angiogenic growth factor promoting ischemic heart repair","volume":"3","author":"Wu","year":"2024","journal-title":"Nat Cardiovasc Res"},{"key":"2026062610073748900_cvag100-B18","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2026062610073748900_cvag100-B19","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1161\/CIRCULATIONAHA.119.045116","article-title":"Agrin promotes coordinated therapeutic processes leading to improved cardiac repair in pigs","volume":"142","author":"Baehr","year":"2020","journal-title":"Circulation"},{"key":"2026062610073748900_cvag100-B20","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.yjmcc.2011.05.003","article-title":"Alpha-1 antitrypsin inhibits caspase-1 and protects from acute myocardial ischemia-reperfusion injury","volume":"51","author":"Toldo","year":"2011","journal-title":"J Mol Cell Cardiol"},{"key":"2026062610073748900_cvag100-B21","doi-asserted-by":"publisher","DOI":"10.3791\/1438","article-title":"LAD-ligation: a murine model of myocardial infarction","author":"Kolk","year":"2009","journal-title":"J Vis Exp"},{"key":"2026062610073748900_cvag100-B22","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1007\/s00330-018-5875-3","article-title":"Prognosis-based definition of left ventricular remodeling after ST-elevation myocardial infarction","volume":"29","author":"Reindl","year":"2019","journal-title":"Eur Radiol"},{"key":"2026062610073748900_cvag100-B23","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1016\/j.jcmg.2019.02.025","article-title":"Prognostic value of initial left ventricular remodeling in patients with reperfused STEMI","volume":"12","author":"Rodriguez-Palomares","year":"2019","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026062610073748900_cvag100-B24","doi-asserted-by":"crossref","first-page":"1215802","DOI":"10.1155\/2020\/1215802","article-title":"Adverse cardiac remodelling after acute myocardial infarction: old and new biomarkers","volume":"2020","author":"Berezin","year":"2020","journal-title":"Dis Markers"},{"key":"2026062610073748900_cvag100-B25","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1161\/CIRCRESAHA.117.312586","article-title":"Mechanisms of cardiac repair and regeneration","volume":"122","author":"Broughton","year":"2018","journal-title":"Circ Res"},{"key":"2026062610073748900_cvag100-B26","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1016\/j.jacc.2019.03.503","article-title":"Pro-angiogenic macrophage phenotype to promote myocardial repair","volume":"73","author":"Ferraro","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026062610073748900_cvag100-B27","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/nature14483","article-title":"Cardiac lymphatics are heterogeneous in origin and respond to injury","volume":"522","author":"Klotz","year":"2015","journal-title":"Nature"},{"key":"2026062610073748900_cvag100-B28","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ijcard.2019.04.089","article-title":"Recombinant Fc-Elabela fusion protein has extended plasma half-life andmitigates post-infarct heart dysfunction in rats","volume":"292","author":"Xi","year":"2019","journal-title":"Int J Cardiol"},{"key":"2026062610073748900_cvag100-B29","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1038\/s41401-019-0230-z","article-title":"Irisin exerts a therapeutic effect against myocardial infarction via promoting angiogenesis","volume":"40","author":"Liao","year":"2019","journal-title":"Acta Pharmacol Sin"},{"key":"2026062610073748900_cvag100-B30","first-page":"36","article-title":"Erythropoietin promotes myocardial infarction repair in mice by improving the function of Sca-1(+) stem cells","volume":"75","author":"Zuo","year":"2023","journal-title":"Sheng li xue bao: [Acta physiologica Sinica]"},{"key":"2026062610073748900_cvag100-B31","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/j.1582-4934.2008.00546.x","article-title":"Intracardiac injection of erythropoietin induces stem cell recruitment and improves cardiac functions in a rat myocardial infarction model","volume":"13","author":"Klopsch","year":"2009","journal-title":"J Cell Mol Med"},{"key":"2026062610073748900_cvag100-B32","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1126\/science.abn3027","article-title":"Meteorin-like promotes heart repair through endothelial KIT receptor tyrosine kinase","volume":"376","author":"Reboll","year":"2022","journal-title":"Science"},{"key":"2026062610073748900_cvag100-B33","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s10020-021-00352-w","article-title":"Gastrin exerts a protective effect against myocardial infarction via promoting angiogenesis","volume":"27","author":"Fu","year":"2021","journal-title":"Mol Med"},{"key":"2026062610073748900_cvag100-B34","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/nm1199","article-title":"G-CSF prevents cardiac remodeling after myocardial infarction by activating the Jak-Stat pathway in cardiomyocytes","volume":"11","author":"Harada","year":"2005","journal-title":"Nat Med"},{"key":"2026062610073748900_cvag100-B35","first-page":"317905","article-title":"OSM enhances angiogenesis and improves cardiac function after myocardial infarction","volume":"2015","author":"Zhang","year":"2015","journal-title":"Biomed Res Int"},{"key":"2026062610073748900_cvag100-B36","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1161\/CIRCRESAHA.108.188243","article-title":"IL-10 inhibits inflammation and attenuates left ventricular remodeling after myocardial infarction via activation of STAT3 and suppression of HuR","volume":"104","author":"Krishnamurthy","year":"2009","journal-title":"Circ Res"},{"key":"2026062610073748900_cvag100-B37","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/bph.14549","article-title":"Exogenous IL-19 attenuates acute ischaemic injury and improves survival in male mice with myocardial infarction","volume":"176","author":"An","year":"2019","journal-title":"Br J Pharmacol"},{"key":"2026062610073748900_cvag100-B38","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.004406","article-title":"Interleukin-37 and dendritic cells treated with interleukin-37 plus troponin I ameliorate cardiac remodeling after myocardial infarction","volume":"5","author":"Zhu","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"2026062610073748900_cvag100-B39","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1161\/CIRCRESAHA.111.243162","article-title":"Regulation of the inflammatory response in cardiac repair","volume":"110","author":"Frangogiannis","year":"2012","journal-title":"Circ Res"},{"key":"2026062610073748900_cvag100-B40","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1093\/cvr\/cvab237","article-title":"Interleukin-5-induced eosinophil population improves cardiac function after myocardial infarction","volume":"118","author":"Xu","year":"2022","journal-title":"Cardiovasc Res"},{"key":"2026062610073748900_cvag100-B41","doi-asserted-by":"crossref","first-page":"4552","DOI":"10.7150\/thno.24723","article-title":"Liver-heart crosstalk controls IL-22 activity in cardiac protection after myocardial infarction","volume":"8","author":"Tang","year":"2018","journal-title":"Theranostics"},{"key":"2026062610073748900_cvag100-B42","doi-asserted-by":"crossref","first-page":"5262","DOI":"10.3892\/mmr.2016.5163","article-title":"Apelin-13 protects against myocardial infarction-induced myocardial fibrosis","volume":"13","author":"Zhang","year":"2016","journal-title":"Mol Med Rep"},{"key":"2026062610073748900_cvag100-B43","doi-asserted-by":"crossref","first-page":"105793","DOI":"10.1016\/j.biocel.2020.105793","article-title":"Cholecystokinin octapeptide reduces myocardial fibrosis and improves cardiac remodeling in post myocardial infarction rats","volume":"125","author":"Wang","year":"2020","journal-title":"Int J Biochem Cell Biol"},{"key":"2026062610073748900_cvag100-B44","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1016\/j.peptides.2009.09.004","article-title":"Ghrelin inhibits post-infarct myocardial remodeling and improves cardiac function through anti-inflammation effect","volume":"30","author":"Huang","year":"2009","journal-title":"Peptides"},{"key":"2026062610073748900_cvag100-B45","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s13105-023-00945-5","article-title":"Klotho improves cardiac fibrosis, inflammatory cytokines, ferroptosis, and oxidative stress in mice with myocardial infarction","volume":"79","author":"Wang","year":"2023","journal-title":"J Physiol Biochem"},{"key":"2026062610073748900_cvag100-B46","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ejphar.2016.12.024","article-title":"Effects of neuregulin GGF2 (cimaglermin alfa) dose and treatment frequency on left ventricular function in rats following myocardial infarction","volume":"796","author":"Parry","year":"2017","journal-title":"Eur J Pharmacol"},{"key":"2026062610073748900_cvag100-B47","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0055741","article-title":"Intravenous glial growth factor 2 (GGF2) isoform of neuregulin-1\u03b2 improves left ventricular function, gene and protein expression in rats after myocardial infarction","volume":"8","author":"Hill","year":"2013","journal-title":"PLoS One"},{"key":"2026062610073748900_cvag100-B48","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1056\/NEJMra071667","article-title":"Myocardial reperfusion injury","volume":"357","author":"Yellon","year":"2007","journal-title":"N Engl J Med"},{"key":"2026062610073748900_cvag100-B49","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/s41569-020-0403-y","article-title":"Myocardial ischaemia\u2013reperfusion injury and cardioprotection in perspective","volume":"17","author":"Heusch","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"2026062610073748900_cvag100-B50","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ejphar.2015.04.034","article-title":"Post-infarct treatment with [Pyr(1)]apelin-13 improves myocardial function by increasing neovascularization and overexpression of angiogenic growth factors in rats","volume":"761","author":"Azizi","year":"2015","journal-title":"Eur J Pharmacol"},{"key":"2026062610073748900_cvag100-B51","doi-asserted-by":"crossref","first-page":"H1471","DOI":"10.1152\/ajpheart.00097.2011","article-title":"Apelin-13 protects the heart against ischemia-reperfusion injury through inhibition of ER-dependent apoptotic pathways in a time-dependent fashion","volume":"301","author":"Tao","year":"2011","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2026062610073748900_cvag100-B52","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/FJC.0000000000000474","article-title":"A preclinical translational study of the cardioprotective effects of plasma-derived alpha-1 anti-trypsin in acute myocardial infarction","volume":"69","author":"Mauro","year":"2017","journal-title":"J Cardiovasc Pharmacol"},{"key":"2026062610073748900_cvag100-B53","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1161\/CIRCULATIONAHA.117.029980","article-title":"EMC10 (endoplasmic reticulum membrane protein complex subunit 10) is a bone marrow-derived angiogenic growth factor promoting tissue repair after myocardial infarction","volume":"136","author":"Reboll","year":"2017","journal-title":"Circulation"},{"key":"2026062610073748900_cvag100-B54","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ymthe.2018.10.020","article-title":"IGF1 treatment improves cardiac remodeling after infarction by targeting myeloid cells","volume":"27","author":"Heinen","year":"2019","journal-title":"Mol Ther"},{"key":"2026062610073748900_cvag100-B55","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/sctm.20-0456","article-title":"Neurotrophin-3 contributes to benefits of human embryonic stem cell-derived cardiovascular progenitor cells against reperfused myocardial infarction","volume":"10","author":"Bi","year":"2021","journal-title":"Stem Cells Transl Med"},{"key":"2026062610073748900_cvag100-B56","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/SHK.0b013e31802fa038","article-title":"The effects of the fibrin-derived peptide Bbeta(15\u201342) in acute and chronic rodent models of myocardial ischemia-reperfusion","volume":"27","author":"Zacharowski","year":"2007","journal-title":"Shock"},{"key":"2026062610073748900_cvag100-B57","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jacc.2006.04.008","article-title":"Erythropoietin enhances neovascularization of ischemic myocardium and improves left ventricular dysfunction after myocardial infarction in dogs","volume":"48","author":"Hirata","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"2026062610073748900_cvag100-B58","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s00380-011-0197-2","article-title":"Effects of erythropoietin on angiogenesis after myocardial infarction in porcine","volume":"27","author":"Kawachi","year":"2012","journal-title":"Heart Vessels"},{"key":"2026062610073748900_cvag100-B59","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1124\/jpet.120.000047","article-title":"Targeted injection of a truncated form of tissue inhibitor of metalloproteinase 3 alters post-myocardial infarction remodeling","volume":"375","author":"Lobb","year":"2020","journal-title":"J Pharmacol Exp Ther"},{"key":"2026062610073748900_cvag100-B60","doi-asserted-by":"crossref","first-page":"H690","DOI":"10.1152\/ajpheart.00114.2017","article-title":"Intracoronary delivery of recombinant TIMP-3 after myocardial infarction: effects on myocardial remodeling and function","volume":"313","author":"Barlow","year":"2017","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2026062610073748900_cvag100-B61","first-page":"257","article-title":"Granulocyte-colony stimulating factor administration after myocardial infarction in a porcine ischemia-reperfusion model: functional and pathological effects of dose timing","volume":"69","author":"Beohar","year":"2007","journal-title":"Catheter Cardiovasc Interv"},{"key":"2026062610073748900_cvag100-B62","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1161\/CIRCINTERVENTIONS.110.960765","article-title":"Potent long-term cardioprotective effects of single low-dose insulin-like growth factor-1 treatment postmyocardial infarction","volume":"4","author":"O'Sullivan","year":"2011","journal-title":"Circ Cardiovasc Interv"},{"key":"2026062610073748900_cvag100-B63","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.jacbts.2022.11.006","article-title":"PDGF-AB reduces myofibroblast differentiation without increasing proliferation after myocardial infarction","volume":"8","author":"Hume","year":"2023","journal-title":"JACC Basic Transl Sci"},{"key":"2026062610073748900_cvag100-B64","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aay2140","article-title":"Platelet-derived growth factor-AB improves scar mechanics and vascularity after myocardial infarction","volume":"12","author":"Thavapalachandran","year":"2020","journal-title":"Sci Transl Med"},{"key":"2026062610073748900_cvag100-B65","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3390\/antiox14020213","article-title":"Molecular insights into ischemia\u2013reperfusion injury in coronary artery disease: mechanisms and therapeutic implications: a comprehensive review","volume":"14","author":"Ghanta","year":"2025","journal-title":"Antioxidants"},{"key":"2026062610073748900_cvag100-B66","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41392-022-00925-z","article-title":"Signaling pathways and targeted therapy for myocardial infarction","volume":"7","author":"Zhang","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"2026062610073748900_cvag100-B67","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.3390\/cells11091553","article-title":"Insight into the role of the PI3K\/Akt pathway in ischemic injury and post-infarct left ventricular remodeling in normal and diabetic heart","volume":"11","author":"Walkowski","year":"2022","journal-title":"Cells"},{"key":"2026062610073748900_cvag100-B68","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1097\/TP.0000000000004497","article-title":"rhMYDGF alleviates I\/R-induced kidney injury by inhibiting inflammation and apoptosis via the Akt pathway","volume":"107","author":"Wang","year":"2023","journal-title":"Transplantation"},{"key":"2026062610073748900_cvag100-B69","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2023.1164166","article-title":"The role of the ERK signaling pathway in promoting angiogenesis for treating ischemic diseases","volume":"11","author":"Song","year":"2023","journal-title":"Front Cell Dev Biol"},{"key":"2026062610073748900_cvag100-B70","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.molimm.2025.08.018","article-title":"JAK\/STAT pathway in myocardial infarction: crossroads of immune signaling and cardiac remodeling","volume":"186","author":"Yang","year":"2025","journal-title":"Mol Immunol"},{"key":"2026062610073748900_cvag100-B71","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.yjmcc.2010.10.033","article-title":"Transforming growth factor (TGF)-\u03b2 signaling in cardiac remodeling","volume":"51","author":"Dobaczewski","year":"2011","journal-title":"J Mol Cell Cardiol"},{"key":"2026062610073748900_cvag100-B72","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines12051055","article-title":"Vascular endothelial growth factor (VEGF) and its role in the cardiovascular system","volume":"12","author":"Florek","year":"2024","journal-title":"Biomedicines"},{"key":"2026062610073748900_cvag100-B73","doi-asserted-by":"crossref","first-page":"535","DOI":"10.2174\/1389203723666220817085941","article-title":"The role of NF-\u03baB in myocardial ischemia\/reperfusion injury","volume":"23","author":"Dong","year":"2022","journal-title":"Curr Protein Pept Sci"},{"key":"2026062610073748900_cvag100-B74","doi-asserted-by":"crossref","first-page":"9100","DOI":"10.7150\/thno.44281","article-title":"Mydgf promotes cardiomyocyte proliferation and neonatal heart regeneration","volume":"10","author":"Wang","year":"2020","journal-title":"Theranostics"},{"key":"2026062610073748900_cvag100-B75","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.696605","article-title":"Current understanding of IL-37 in human health and disease","volume":"12","author":"Su","year":"2021","journal-title":"Front Immunol"},{"key":"2026062610073748900_cvag100-B76","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/cei.12284","article-title":"Interleukin-37 ameliorates myocardial ischaemia\/reperfusion injury in mice","volume":"176","author":"Wu","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"2026062610073748900_cvag100-B77","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1001\/jama.2011.592","article-title":"Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial","volume":"305","author":"Najjar","year":"2011","journal-title":"JAMA"},{"key":"2026062610073748900_cvag100-B78","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1161\/CIRCINTERVENTIONS.109.904425","article-title":"Erythropoietin in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomized, double-blind trial","volume":"3","author":"Ott","year":"2010","journal-title":"Circ Cardiovasc Interv"},{"key":"2026062610073748900_cvag100-B79","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12872-016-0464-3","article-title":"Effect of erythropoietin in patients with acute myocardial infarction: five-year results of the REVIVAL-3 trial","volume":"17","author":"Steppich","year":"2017","journal-title":"BMC Cardiovasc Disord"},{"key":"2026062610073748900_cvag100-B80","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.ahj.2014.04.020","article-title":"Safety and clinical outcome of erythropoiesis-stimulating agents in patients with ST-elevation myocardial infarction: a meta-analysis of individual patient data","volume":"168","author":"Fokkema","year":"2014","journal-title":"Am Heart J"},{"key":"2026062610073748900_cvag100-B81","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.carrev.2015.01.008","article-title":"Administration of erythropoietin in patients with myocardial infarction: does it make sense? An updated and comprehensive meta-analysis and systematic review","volume":"16","author":"Ali-Hassan-Sayegh","year":"2015","journal-title":"Cardiovasc Revasc Med"},{"key":"2026062610073748900_cvag100-B82","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jacc.2008.12.017","article-title":"Effect of intravenous FX06 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction results of the F.I.R.E. (efficacy of FX06 in the prevention of myocardial reperfusion injury) trial","volume":"53","author":"Atar","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"2026062610073748900_cvag100-B83","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1161\/CIRCRESAHA.118.314617","article-title":"G-CSF for extensive STEMI","volume":"125","author":"Achilli","year":"2019","journal-title":"Circ Res"},{"key":"2026062610073748900_cvag100-B84","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1001\/jama.295.9.1003","article-title":"Stem cell mobilization by granulocyte colony-stimulating factor in patients with acute myocardial infarction: a randomized controlled trial","volume":"295","author":"Zohlnh\u00f6fer","year":"2006","journal-title":"JAMA"},{"key":"2026062610073748900_cvag100-B85","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1093\/eurjhf\/hfq150","article-title":"Granulocyte colony-stimulating factor attenuates left ventricular remodelling after acute anterior STEMI: results of the single-blind, randomized, placebo-controlled multicentre STem cEll Mobilization in Acute Myocardial Infarction (STEM-AMI) trial","volume":"12","author":"Achilli","year":"2010","journal-title":"Eur J Heart Fail"},{"key":"2026062610073748900_cvag100-B86","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.amjcard.2014.09.043","article-title":"Effects of prolastin C (plasma-derived alpha-1 antitrypsin) on the acute inflammatory response in patients with ST-segment elevation myocardial infarction (from the VCU-alpha 1-RT pilot study)","volume":"115","author":"Abbate","year":"2015","journal-title":"Am J Cardiol"},{"key":"2026062610073748900_cvag100-B87","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.hlc.2022.12.015","article-title":"New drug targets and preclinical modelling recommendations for treating acute myocardial infarction","volume":"32","author":"Cao","year":"2023","journal-title":"Heart Lung Circ"},{"key":"2026062610073748900_cvag100-B88","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1161\/01.RES.0000137171.97172.d7","article-title":"Myocardial protection at a crossroads: the need for translation into clinical therapy","volume":"95","author":"Bolli","year":"2004","journal-title":"Circ Res"},{"key":"2026062610073748900_cvag100-B89","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1093\/cvr\/cvx049","article-title":"Novel targets and future strategies for acute cardioprotection: position paper of the European Society of Cardiology working group on cellular biology of the heart","volume":"113","author":"Hausenloy","year":"2017","journal-title":"Cardiovasc Res"},{"key":"2026062610073748900_cvag100-B90","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00395-018-0696-8","article-title":"Practical guidelines for rigor and reproducibility in preclinical and clinical studies on cardioprotection","volume":"113","author":"B\u00f8tker","year":"2018","journal-title":"Basic Res Cardiol"},{"key":"2026062610073748900_cvag100-B91","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s00395-021-00893-5","article-title":"IMproving Preclinical Assessment of Cardioprotective Therapies (IMPACT) criteria: guidelines of the EU-CARDIOPROTECTION COST action","volume":"116","author":"Lecour","year":"2021","journal-title":"Basic Res Cardiol"},{"key":"2026062610073748900_cvag100-B92","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s00395-025-01102-3","article-title":"IMproving Preclinical Assessment of Cardioprotective Therapies (IMPACT): a small animal acute myocardial infarction randomized-controlled multicenter study on the effect of ischemic preconditioning","volume":"120","author":"Hernandez-Resendiz","year":"2025","journal-title":"Basic Res Cardiol"},{"key":"2026062610073748900_cvag100-B93","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1007\/s00395-024-01083-9","article-title":"The IMproving Preclinical Assessment of Cardioprotective Therapies (IMPACT): multicenter pig study on the effect of ischemic preconditioning","volume":"119","author":"Kleinbongard","year":"2024","journal-title":"Basic Res Cardiol"},{"key":"2026062610073748900_cvag100-B94","article-title":"The ARRIVE guidelines 2.0: updated guidelines for reporting animal research","volume":"18","author":"Percie du Sert","year":"2020","journal-title":"PLoS Biol"},{"key":"2026062610073748900_cvag100-B95","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1136\/heartjnl-2024-323926","article-title":"Granulocyte colony-stimulating factor for stem cell mobilisation in acute myocardial infarction: a randomised controlled trial","volume":"110","author":"Achilli","year":"2024","journal-title":"Heart"},{"key":"2026062610073748900_cvag100-B96","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/164_2019_277","article-title":"General principles of preclinical study design","volume":"257","author":"Huang","year":"2020","journal-title":"Handb Exp Pharmacol"},{"key":"2026062610073748900_cvag100-B97","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/cts.12582","article-title":"Design and conduct considerations for first-in-human trials","volume":"12","author":"Shen","year":"2019","journal-title":"Clin Transl Sci"},{"key":"2026062610073748900_cvag100-B98","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/s41392-022-00972-6","article-title":"Signaling cascades in the failing heart and emerging therapeutic strategies","volume":"7","author":"He","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"2026062610073748900_cvag100-B99","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1111\/cts.13055","article-title":"Opportunities and challenges in translational science","volume":"14","author":"Austin","year":"2021","journal-title":"Clin Transl Sci"},{"key":"2026062610073748900_cvag100-B100","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1017\/cts.2020.523","article-title":"A framework for clinical and translational research in the era of rigor and reproducibility","volume":"5","author":"Wichman","year":"2021","journal-title":"J Clin Transl Sci"},{"key":"2026062610073748900_cvag100-B101","first-page":"100278","article-title":"Cardioprotective strategies in myocardial ischemia-reperfusion injury: implications for improving clinical translation","volume":"11","author":"Tong","year":"2025","journal-title":"J Mol Cell Cardiol Plus"},{"key":"2026062610073748900_cvag100-B102","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1745-6215-11-37","article-title":"Reporting bias in medical research\u2014a narrative review","volume":"11","author":"McGauran","year":"2010","journal-title":"Trials"},{"key":"2026062610073748900_cvag100-B103","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jacc.2019.05.024","article-title":"Cardiac MRI endpoints in myocardial infarction experimental and clinical trials: JACC scientific expert panel","volume":"74","author":"Ibanez","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026062610073748900_cvag100-B104","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1016\/j.jacc.2016.01.069","article-title":"Relationship between infarct size and outcomes following primary PCI: patient-level analysis from 10 randomized trials","volume":"67","author":"Stone","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2026062610073748900_cvag100-B105","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.002708","article-title":"Sample size in clinical cardioprotection trials using myocardial salvage index, infarct size, or biochemical markers as endpoint","volume":"5","author":"Engblom","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"2026062610073748900_cvag100-B106","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.jcmg.2017.01.008","article-title":"Myocardial infarct size by CMR in clinical cardioprotection studies: insights from randomized controlled trials","volume":"10","author":"Bulluck","year":"2017","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026062610073748900_cvag100-B107","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1136\/heartjnl-2015-307855","article-title":"Reducing myocardial infarct size: challenges and future opportunities","volume":"102","author":"Bulluck","year":"2016","journal-title":"Heart"},{"key":"2026062610073748900_cvag100-B108","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1161\/CIRCULATIONAHA.117.033502","article-title":"2017 cardiovascular and stroke endpoint definitions for clinical trials","volume":"137","author":"Hicks","year":"2018","journal-title":"Circulation"},{"key":"2026062610073748900_cvag100-B109","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1002\/psp4.12701","article-title":"A framework to guide dose & regimen strategy for clinical drug development","volume":"10","author":"Sander","year":"2021","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"2026062610073748900_cvag100-B110","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s10557-022-07329-9","article-title":"Recombinant apyrase (AZD3366) against myocardial reperfusion injury","volume":"37","author":"Birnbaum","year":"2023","journal-title":"Cardiovasc Drugs Ther"},{"key":"2026062610073748900_cvag100-B111","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.016047","article-title":"Recombinant extracellular domain (p75ECD) of the neurotrophin receptor p75 attenuates myocardial ischemia-reperfusion injury by inhibiting the p-JNK\/caspase-3 signaling pathway in rat microvascular pericytes","volume":"9","author":"Fang","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2026062610073748900_cvag100-B112","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s10557-005-3189-6","article-title":"Cardioprotection by recombinant human erythropoietin following acute experimental myocardial infarction: dose response and therapeutic window","volume":"19","author":"Moon","year":"2005","journal-title":"Cardiovasc Drugs Ther"},{"key":"2026062610073748900_cvag100-B113","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.ymthe.2021.10.005","article-title":"Neuropeptide Y attenuates cardiac remodeling and deterioration of function following myocardial infarction","volume":"30","author":"Qin","year":"2022","journal-title":"Mol Ther"},{"key":"2026062610073748900_cvag100-B114","article-title":"Duration of ischemia affects outcomes independent of infarct size in stroke","volume":"2","author":"Kim","year":"2022","journal-title":"Stroke Vasc Interv Neurol"},{"key":"2026062610073748900_cvag100-B115","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1161\/STROKEAHA.115.011721","article-title":"Association between time to reperfusion and outcome is primarily driven by the time from imaging to reperfusion","volume":"47","author":"Ribo","year":"2016","journal-title":"Stroke"},{"key":"2026062610073748900_cvag100-B116","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1161\/01.CIR.92.4.710","article-title":"Relation between ischemia time, infarct size, and left ventricular function in humans","volume":"92","author":"Hasche","year":"1995","journal-title":"Circulation"},{"key":"2026062610073748900_cvag100-B117","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1471-2288-14-43","article-title":"SYRCLE's risk of bias tool for animal studies","volume":"14","author":"Hooijmans","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"2026062610073748900_cvag100-B118","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s00395-024-01050-4","article-title":"\u201cExpression of concern\u201d: publication bias for positive preclinical cardioprotection studies","volume":"119","author":"Skyschally","year":"2024","journal-title":"Basic Res Cardiol"},{"key":"2026062610073748900_cvag100-B119","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1111\/bph.15595","article-title":"Preclinical models of myocardial infarction: from mechanism to translation","volume":"179","author":"Martin","year":"2022","journal-title":"Br J Pharmacol"},{"key":"2026062610073748900_cvag100-B120","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.jacbts.2020.04.011","article-title":"Large animal models of heart failure: a translational bridge to clinical success","volume":"5","author":"Silva","year":"2020","journal-title":"JACC Basic Transl Sci"}],"container-title":["Cardiovascular Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cardiovascres\/advance-article-pdf\/doi\/10.1093\/cvr\/cvag100\/68246827\/cvag100.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cardiovascres\/advance-article-pdf\/doi\/10.1093\/cvr\/cvag100\/68246827\/cvag100.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cardiovascres\/advance-article-pdf\/doi\/10.1093\/cvr\/cvag100\/68246827\/cvag100.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T14:07:55Z","timestamp":1782482875000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cardiovascres\/article\/122\/9\/1143\/8672544"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,7]]},"references-count":120,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,5,7]]},"published-print":{"date-parts":[[2026,6,26]]}},"URL":"https:\/\/doi.org\/10.1093\/cvr\/cvag100","relation":{},"ISSN":["0008-6363","1755-3245"],"issn-type":[{"value":"0008-6363","type":"print"},{"value":"1755-3245","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,5,7]]}}}